anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To separate pentamine from the fraction of a polyamine, by culturing microorganisms at a relatively high temperature, suspending and disintegrating the microbial cells in water, centrifuging the suspension in the presence of 10% trichloroacetic acid, passing the supernatant through a cation exchange resin column, and eluting with 6N hydrochloric acid. CONSTITUTION:A highly thermophilic bacterial strain, Thermus thermopilus HB8, is cultured, suspended and disintegrated in water, and centrifuged. The precipitate is suspended in 5% trichloroacetic acid and centrifuged to obtain the extract. The extract is diluted with water and passed through a column packed with Dowex 50WX4H<+> resin. The column is washed successively with water, a phosphate buffer solution and 2N- HCl, and the adsorbed polyamine is eluted with 6N-HCl. The obtained fraction is evaporated under reduced pressure, and the residue is dissolved in water, passed through a column packed with Diaion CK-10SH<+>, eluted with 0.1M potassium citrate- HCl buffer solution, and the fraction containing caldopentamine only is collected. The same procedures are repeated, and the fraction containing caldopentamine is evaporated under reduced pressure. The residue is dissolved in the smallest possible amount of 50% hot ethanol, and cooled. The obtained crystal of caldo-pentamine hydrochloride is separated by filtration and dried.
Clinical studies of clomipramine hydrochloride did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects; 152 patients at least 60 years of age participating in various U.S. clinical trials received clomipramine hydrochloride for periods of several months to several years. No unusual age- related adverse events were identified in this population. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Clomipramine hydrochloride has been associated with cases of clinically significant hyponatremia. Elderly patients may be at greater risk for this adverse reaction (see PRECAUTIONS, Hyponatremia).
BACKGROUND: Stress hyperglycemia is prevalent in critical illnesses and has been associated with adverse short- and long-term outcomes in individuals with acute coronary syndrome (ACS). However, there is limited evidence for the predictive value of stress hyperglycemia and hospitalization mortality in patients with chronic kidney disease (CKD) and ACS. This study aimed to explore the association between hospitalized mortality, stress hyperglycemia ratio (SHR), and admission blood glucose (ABG) in patients with CKD and ACS.
METHODS: This study included 655 hospitalized patients who were diagnosed with ACS and CKD. Patients with incomplete data were excluded, resulting in the analysis of 550 patients. The primary outcome measured was in-hospital mortality.
RESULTS: The median age of the cohort included in the analysis was 71 years, with a male proportion of 66.2 %, and a mean estimated glomerular filtration rate (eGFR) of 27.8 mL/min/1.73 m2. Patients classified as having stage 3, stage 4, and stage 5 chronic kidney disease (CKD) comprised 46.9 %, 17.1 %, and 36.0 % of the population, respectively. The overall in-hospital mortality rate was 10.7 % (n = 59). Both SHR (OR = 2.67; 95 % CI 1.51-4.74; p < 0.001) and ABG (OR = 1.09; 95 % CI 1.04-1.14; p < 0.001) were significantly associated with in-hospital mortality in CKD and ACS patients. SHR and ABG showed a linear relationship with in-hospital mortality, with SHR demonstrating superior reclassification ability over ABG. The inclusion of SHR or ABG, irrespective of diabetes mellitus status, substantially enhanced the predictive performance of the Global Registry of Acute Coronary Events (GRACE) score model.
CONCLUSIONS: In patients with ACS and CKD, a robust correlation was observed between SHR, ABG, and in-hospital mortality. Both SHR and ABG improved the predictive accuracy of the GRACE score in forecasting inpatient mortality in this population.
PURPOSE:To produce the titled compound useful as a remedy for allergic diseases, easily, in high efficiency, under an easily controllable mild condition, without side reactions, by treating a phosphorus compound with a basic substance, and reacting the product with a nucleus-substituted benzaldehyde compound. CONSTITUTION:The phosphorus compound of formula I [R<1> is H or 1-3C lower alkyl; R<2> is 1-3C lower alkyl; Z is group of formula II (X<1> is 1-10C alkyl, phenyl, etc.; X<2> is 1-10C alkoxy; Hal is Cl or Br), etc.] is treated with a basic substance to obtain the phosphorus ylide derivative of formula III (Z' is group of formula IV, etc.). The compound is made to react with the nucleus-substituted benzaldehyde compound of formula V (Y is 1-4C straight or branched chain lower alkoxyl, etc.; n is 2 or 3) to afford the objective aromatic carboxylic acid amide derivative of formula VI. Since the process can be carried out under mild condition, the amount of by-product can be reduced and the product can be purified easily. There is absolutely no generation of harmful gas.
Acetamiprid (ACP) is a novel neonicotinoid insecticide used for controlling insect pests. Resveratrol (RSV) is a natural polyphenol that possesses anti-oxidant, anti-inflammatory and anti-apoptotic actions. The current research explores the mechanism of ACP-induced cardiotoxicity and the alleviative effects of RSV. Male rats were allocated to four groups of ten each. Rats were treated daily for 90 days via oral route. Control rats received distilled water, ACP rats received 25 mg acetamiprid/kg, RSV rats received 20 mg resveratrol/kg and ACP + RSV rats received both ACP and RSV. ACP exposure increased serum creatine phosphokinase activity and cardiac troponin level. It also induced oxidative stress, as evidenced by the glutathione reduction, and malondialdehyde elevation, as well as the detrimental histopathological and immunohistochemical changes in the myocardium. Gene expression analysis revealed down-regulation in the mRNA expression of the survival-related genes α7 nAChR, Erk and Bcl-2, and up-regulation in the apoptosis-related genes Jnk, Bax and Caspase-3. Conversely, the concomitant administration of ACP with RSV alleviated most of the aforementioned toxic impacts. It can be concluded that ACP induces cardiotoxicity by dysregulating the mRNA expression of α7 nAChR and its downstream targets. Additionally, RSV is proved to be a promising ameliorative agent against ACP-induced cardiotoxicity.
Healthcare-acquired infections are a major problem in healthcare facility settings around the world. The Democratic Republic of the Congo (DRC) has over 2 million diarrhea patients hospitalized each year. These healthcare settings become high-risk environments for spreading diarrheal illnesses such as cholera. The objective of the Preventative Intervention for Cholera for 7 Days (PICHA7) program is to develop evidence-based water, sanitation, and hygiene (WASH) interventions to reduce cholera and other severe diarrheal diseases in the DRC. The study objective was to evaluate the effectiveness of PICHA7 program delivery in increasing handwashing with a cleansing agent at stool/vomit- and food-related events in a healthcare facility setting among diarrhea patients and patient attendants. A pilot of the PICHA7 program was conducted among 284 participants in 27 healthcare facilities from March 2020 to November 2021 in urban Bukavu in the South Kivu Province of the DRC. The standard arm received the standard message provided in the DRC to diarrhea patients on the use of oral rehydration solution and a basic WASH message at healthcare facility discharge. The PICHA7 arm received the PICHA7 WASH pictorial module delivered by a health promoter focused on handwashing with a cleansing agent at the bedside of the diarrhea patient in the healthcare facility and provision of a soapy water bottle (water and detergent powder). Within 24 h of intervention delivery, a three-hour structured observation of handwashing practices at stool/vomit- and food-related events (key events) was conducted in healthcare facilities of diarrhea patients and their attendants. Compared to the standard arm, there was significantly more handwashing with a cleansing agent at key events in the PICHA7 arm (40% vs. 15%) (odds ratio: 5.04; (95% confidence interval (CI): 2.01, 12.7)). These findings demonstrate that delivery of the PICHA7 WASH pictorial module and provision of a soapy water bottle to diarrhea patients and their attendants presents a promising approach to increase handwashing with a cleansing agent among this high-risk population in healthcare facilities in the eastern DRC.
At the beginning of the Participants surgical procedure, a picture will be obtained using intraoperative angiography using ICG dye which the camera can detect. This dye will be provided through intravenous access. The picture will be taken of the wound to determine preoperative blood flow to the area where the incision is planned. After the wound has been closed postoperatively, a final picture, using the procedure described above, will be taken to determine blood flow after closure of the wound. These images will be obtained using intraoperative angiography. The Participant will be followed after the surgical procedure at standard intervals as determined by the surgeon until the wound heals or requires further intervention.
Water-soluble iron-carbohydrate complex (A) prepared from maltodextrin (MD) oxidation product. Water-soluble iron-carbohydrate complex (A) prepared from an aqueous solution of an iron(III) salt and an aqueous solution of the oxidation product obtained by treating at least one maltodextrin (MD) with aqueous hypochlorite solution at alkaline pH. If only one MD is used, it has dextrose equivalent (DE) 5-20; if a mixture is used it also has DE 5-20, with DE of the individual components 2-40. ACTIVITY : Antianemic. No test details given. MECHANISM OF ACTION : None given.
The present invention relates to a method for identification of cellular protein antigens to which patients with cancer, or patients at risk for cancer, may develop autoantibodies.  The method of the invention involves the use of patient derived sera for the identification of the cellular protein antigens using two-dimensional gel electrophoresis followed by Western Blot analysis. The identification of such protein antigens provides novel markers that can be utilized for screening, for diagnostics and prognosis of disease. The invention also provides for the use of the identified protein antigens in immunoassays designed to detect the presence of serum antibodies to the specific protein antigens in sera from individuals that may harbor such antibodies. The invention further relates to the use of the identified antigens as immunogens for stimulation of an immune response in patients expressing such protein antigens. The invention is demonstrated by way of example in which elevated levels of circulating autoantibodies reactive against a tumor specific antigen were identified in sera derived from a lung cancer patient. In addition, elevated levels of circulating autoantibodies reactive against several specific .beta.-tubulin isoforms were detected in the sera of neuroblastoma patients.
For use in patients with diseases including SCID, CGD, CHS and other CID. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m\^2 IV on days -5 through -2 and stem cell infusion on day 0.
The invention relates to veterinary, in particular to methods for diagnostics of infectious diseases in animals. The invention is aimed at solving the task of more effective revealing of bacteria-carrying in case of cattle brucellosis in vaccinated and non-vaccinated livestock due to possibility to detect animals with latent brucellosis. The method is implemented in the following way. All animals, including young stock, both immunised against brucellosis and non-immunised, starting from 2 days of age, are given intramuscular injection of brucellin, and after 30-40 minutes – solution for injections in the dose of 4-6 ml per animal. Brucellin is administered in the dose of 2.5-3.0 ml per animal to young animals of colostrum age, with injection of brucellin in the dose of 4.5-5.0 ml per animal to adult livestock. Solution for injections is a mixture of 36.5-40% aqueous formaldehyde solution and 0.85-0.95% isotonic sodium chloride solution with ratio of weight parts of solutions: 2-6:994-998. 10-28 days after administration of the products serological analysis is carried out.
Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
Argininosuccinate lyase deficiency (ASLD; also known as argininosuccinic aciduria) is the second most common urea cycle disorder (UCD) and accounts for 15-20% of all disorders of ureagenesis. Individuals with ASLD can have unique clinical and physiologic characteristics as compared to other UCDs. Previous work from the members of the UCDC have shown that in spite of having fewer episodes of hyperammonemia as compared to those with proximal blockade of the urea cycle, individuals with ASLD can develop intellectual and learning disabilities. Neurocognitive deficits have been observed even in individuals without any documented hyperammonemia. Furthermore, hepatic abnormalities including hepatomegaly, hepatic injury, fibrosis and even frank cirrhosis, and vascular issues like hypertension are well known in the disorder. Previous work from the members of the UCDC has demonstrated a tissue- and molecular-specific role for ASL in the generation of NO. ASL is not only required for the synthesis of L-arginine, the substrate for the synthesis of NO, but is also an integral member of a complex that is critical for synthesis of NO from arginine. Loss of ASL can thus lead to systemic and tissue-specific NO deficiencies, which could potentially contribute to the complex phenotype including the neurocognitive deficits. A rational therapeutic option would hence be to use a NOS-independent NO supplement.

The purpose of this study is to determine whether a dietary NO supplement, Neo-ASA, would improve general cognition, memory, executive functioning, fine motor functioning, and attention in individuals with ASLD. In this single-center trial, double-blind, randomized, placebo-controlled, crossover study, individuals with ASLD will be assigned to receive a medication containing NO dietary supplement for 24 weeks and a placebo for 24 weeks. General cognition, memory, executive functioning, and fine motor functioning will be assessed and compared at the end of treatment with placebo and Neo-ASA.
<P>PROBLEM TO BE SOLVED: To attain medical care which is efficient and sure for both of a doctor and a patient.  <P>SOLUTION: Hand-written characters inputted by a digital pen system 17 are displayed on a display device 13 of a doctor's terminal in real time, the entered character information is stored into a medical care record information database 21 of a medical information management server 2 as image data and a PDF file. A related section terminal 3 acquires the stored image data by inquiring the medical information management server 2 and displays the obtained data on a display device 33. A related section of nurses or the like performs patient's treatment and generates a performance record indicating that the patient's treatment has been completed and transmits the generated performance record to the doctor's terminal 1, which displays the data. Consequently the doctor can quickly confirm the end of the medical treatment by the display of the performance record.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Traumatic abdominal wall hernia (TAWH) is a protrusion of contents through a defect in the abdominal wall as a consequence of a blunt injury. The objective of this review was to describe demographic and clinical aspects of this rare pathology, identifying the optimal moment for surgical intervention, evaluating the need to use mesh, and analyzing the effectiveness of surgical treatment. Thus, a systematic review using PubMed, Embase, and Scopus databases was carried out between January 2004 and March 2024. Computed tomography is the gold-standard imaging test for diagnosis. Open surgery is generally the preferred approach, particularly in emergencies. Acute TAWH can be treated by primary suture or mesh repair, depending on local conditions, while late cases usually require mesh.
15% of US adults have gallstones, most of which are clinically "silent". Several studies show that menopausal hormone therapy (MHT) increases symptomatic gallstones and cholecystectomy risk. MHT use may be contraindicated in women with gallstones and population studies may be biased by "confounding by contraindication" while the true association between MHT and gallstones remains underestimated. We sought to examine whether MHT use was associated with asymptomatic gallstones using instrumental variable (IV) analysis to account for confounding by contraindication. We used 2018 postmenopausal women from the Third National Health and Nutrition Examination Survey to estimate associations of MHT use with asymptomatic gallstones. A traditional logistic regression analysis was compared to instrumental variable (IV) analysis to account for confounding by contraindication. 12% of women with asymptomatic gallstones and 25% of women without gallstones were current MHT users (P < 0.001). The traditional analysis suggested a decreased odds of asymptomatic gallstones in current versus never users (OR 0.58, 95% CI 0.37, 0.89), but increased odds (OR 1.51, 95% CI 0.44, 5.16) in the IV analysis. The traditional analysis consistently underestimated the odds of asymptomatic gallstones with MHT use compared to the IV analysis. Accounting for confounding by contraindication, we found a suggestive, though imprecise, positive association between MHT use and asymptomatic gallstones among postmenopausal women. Failure to consider contraindication can produce incorrect results.
Chronic pain conditions affect nearly 20% of the population in the United States. Current medical interventions, such as opioid drugs, are effective at relieving pain but are accompanied by many undesirable side effects. This is one reason increased numbers of chronic pain patients have been turning to Cannabis for pain management. Cannabis contains many bioactive chemical compounds; however, current research looking into lesser-studied minor cannabinoids in Cannabis lacks uniformity between experimental groups and/or excludes female mice from investigation. This makes it challenging to draw conclusions between experiments done with different minor cannabinoid compounds between laboratories or parse out potential sex differences that could be present. We chose five minor cannabinoids found in lower quantities within Cannabis: cannabinol (CBN), cannabidivarin (CBDV), cannabigerol (CBG), Δ8-tetrahydrocannabinol (Δ8-THC), and Δ9-tetrahydrocannabivarin (THCV). These compounds were then tested for their cannabimimetic and pain-relieving behaviors in a cannabinoid tetrad assay and a chemotherapy-induced peripheral neuropathy (CIPN) pain model in male and female CD-1 mice. We found that the minor cannabinoids we tested differed in the cannabimimetic behaviors evoked, as well as the extent. We found that CBN, CBG, and high-dose Δ8-THC evoked some tetrad behaviors in both sexes, while THCV and low-dose Δ8-THC exhibited cannabimimetic tetrad behaviors only in females. Only CBN efficaciously relieved CIPN pain, which contrasts with reports from other researchers. Together these findings provide further clarity to the pharmacology of minor cannabinoids and suggest further investigation into their mechanism and therapeutic potential. SIGNIFICANCE STATEMENT: Minor cannabinoids are poorly studied ligands present in lower levels in Cannabis than cannabinoids like THC. In this study, we evaluated five minor cannabinoids (CBN, CBDV, CBG, THCV, and Δ8-THC) for their cannabimimetic and analgesic effects in mice. We found that four of the five minor cannabinoids showed cannabimimetic activity, while one was efficacious in relieving chronic neuropathic pain. This work is important in further evaluating the activity of these drugs, which are seeing wider public use with marijuana legalization.
Important Preparation Information

  * Prior to reconstitution, store vials in the freezer at -25°C to -15°C (-13°F to 5°F). Protect from light.
  * Use aseptic technique for the preparation of LUMISIGHT.
  * The recommended dose depends on the individual patient’s weight. Multiple vials of LUMISIGHT may need to be reconstituted to achieve the individual patient dose.
  * Only use 0.45% Sodium Chloride Injection, USP for reconstitution of LUMISIGHT to prevent high osmolality.



Preparation Instructions

  1. Calculate the dose (1 mg/kg) and the total volume (mL) of LUMISIGHT based on the individual patient’s weight.
  2. Obtain the number of vials required to administer the patient dose.
  3. Allow the vials to acclimate to room temperature between 20°C to 25°C (68°F to 77°F) for approximately 5 minutes.
  4. Reconstitute each vial of LUMISIGHT with 4 mL of 0.45% Sodium Chloride Injection, USP to permit withdrawal of 3.9 mL of LUMISIGHT 10 mg/mL.
  5. Visually inspect the reconstituted solution. It should be a clear, dark blue-colored solution free of particulate matter. Discard if there is any discoloration or particulate matter.
  6. If not immediately used, store the reconstituted LUMISIGHT vial at room temperature at 20°C to 25°C (68°F to 77°F) and use within 4 hours, or store the reconstituted LUMISIGHT vial in the refrigerator at 2°C to 8°C (35°F to 46°F) and use within 24 hours. Protect from light.
  7. Each vial of LUMISIGHT is for a single dose. Discard unused portion.
One sham injection to the study eye at 6-month intervals for 42 months. Syringe containing AA vehicle was not inserted into the eye.
The invention relates to the technical field of microneedle injection of cutaneous penetration, in particular to a microneedle injection bullet, a manufacturing method thereof and a microneedle injection device. The microneedle injection bullet comprises a microneedle array thin film and a substrate. The microneedle array thin film comprises a thin film substrate and a microneedle array on the front face of the thin film substrate. The substrate is provided with a through hole array aligned to the microneedle array. The thin film substrate of the microneedle array thin film is fixed to the substrate. Each microneedle of the microneedle array is embedded into a through hole of the through hole array. The microneedle injection device matched with the microneedle injection bullet comprises the microneedle injection bullet and a microneedle propelling device. The microneedle propelling device separates the microneedles of the microneedle array from the microneedle array thin film and presses the microneedles into skin. The microneedle injection device has the advantages that when the microneedle injection bullet is used for injection, and the microneedles are separated from the microneedle array thin film, so that the microneedles completely enter the skin, medicine contained in the microneedles is completely dissolved and released, and the purpose of precisely controlling the microneedle administration dosage is achieved.